Press release
Are exacerbations the most relevant outcome parameters in COPD clinical trials?
COPD is not curable and it is under-diagnosed meaning sufferer numbers may be much larger than are recorded currently. COPD cannot be cured, but effective treatment can slow its progress and reduce the numbers of deaths. One of the major focuses of research is attempts to improve patients’ quality of life.
Join SMi at their 4th annual COPD: Novel Therapeutics & Management Strategies held in London on the 22nd & 23rd October addressing the hot topics in COPD, and will emphasize developments in new therapies and issues surrounding the management of COPD and management of exacerbations of COPD.
Reasons to attend include:
• Consider developments in the modelling and management of exacerbations of COPD
• Evaluate unique complexities of COPD pathophysiology
• Develop combination and oxygen therapies within COPD - learn about triple therapies and novel therapies within the treatment of COPD
• Hear from leading industry professionals on the current clinical trials process and rapid proof of concept studies
• Analyse all phases of the discovery process, from pre-clinical modelling, phase 2 studies all the way through to modelling clinical outcomes
• Network with and learn from key industry professional and research leading academics
• Discuss the latest in health economics for COPD drugs
For more information visit http://www.smi-online.co.uk/goto/copd-conference18.asp or contact Ninica Hussain on tel. +44 0207 827 6186
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk
SMi Group Ltd
2nd Floor South, Harling House 47-51 Great Suffolk Street,
London, SE1 0BS
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Are exacerbations the most relevant outcome parameters in COPD clinical trials? here
News-ID: 225298 • Views: …
More Releases from SMi Group
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for COPD
Copd Drugs Market Size Analysis by Application, Type, and Region: Forecast to Co …
USA, New Jersey- According to Market Research Intellect, the global Copd Drugs market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
Because respiratory problems are becoming more common worldwide, especially among smokers and older populations, the market for COPD medications is expanding steadily. The need…
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2024-2030 Growth: …
Growth: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Insights :
For stakeholders, an optimistic view is shown by the thorough study of the worldwide "Chronic Obstructive Pulmonary Disease (COPD) Treatment market". The research provides specifics on the market's historical and present conditions as well as projected trends and size. Decision-makers may navigate the competitive environment and investment possibilities in the Chronic Obstructive Pulmonary Disease (COPD) Treatment market with the use of…
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Breathing Sol …
Newark, New Castle, USA - new report, titled Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Obstructive Pulmonary Disease…
Asthma & COPD Drugs Market - Breathe Freely, Live Fully: Empowering Respiratory …
Newark, New Castle, USA - new report, titled Asthma & COPD Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Asthma & COPD Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Asthma & COPD Drugs market. The report offers…
Copd CBD Gummies: Reviews (Shocking Facts) Copd CBD Oil "Ingredients" Pain Relie …
Copd CBD Gummies: With the increasing need for both individual and expert degrees, the stress and also stress are also enhancing. Individuals are using various methods to fight it. However, as a result of much less time for self, it is really hard. Here the natural herbs and supplements have actually discovered their way into our lives. The Copd CBD Oil are instances of super-effective natural supplements. The CBD existing…
Power Harmonica to Cure Chronic Asthma & COPD
Power Harmonica is a free reed wind musical instrument. It is small rectangular shaped musical instrument. It has 48 number of holes which makes it special and different from other harmonica's.
It's a pocket-friendly musical instrument. Power Harmonica is used as a natural treatment for many types of lung disorders and has no side effects. To play Power Harmonica there is no need of having a musical background it can be…
